argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

argenx SE (NASDAQ:ARGX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $530.74.

A number of research firms have commented on ARGX. William Blair cut shares of argenx from an "outperform" rating to a "market perform" rating in a report on Wednesday, December 20th. Piper Sandler raised their price target on shares of argenx from $518.00 to $522.00 and gave the stock an "overweight" rating in a report on Friday, January 26th. JMP Securities restated a "market outperform" rating and issued a $471.00 price target on shares of argenx in a report on Friday, March 22nd. Deutsche Bank Aktiengesellschaft cut shares of argenx from a "buy" rating to a "hold" rating in a report on Wednesday, December 20th. Finally, Wells Fargo & Company lifted their price objective on shares of argenx from $472.00 to $478.00 and gave the company an "overweight" rating in a report on Tuesday, February 20th.

Institutional Trading of argenx

Several hedge funds have recently added to or reduced their stakes in ARGX. JPMorgan Chase & Co. raised its position in shares of argenx by 143.0% in the first quarter. JPMorgan Chase & Co. now owns 1,577 shares of the company's stock valued at $497,000 after purchasing an additional 928 shares during the period. Raymond James & Associates raised its position in shares of argenx by 19.4% in the first quarter. Raymond James & Associates now owns 4,534 shares of the company's stock valued at $1,430,000 after purchasing an additional 738 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in shares of argenx by 46.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 3,544 shares of the company's stock valued at $1,117,000 after purchasing an additional 1,116 shares during the period. Bank of New York Mellon Corp raised its position in shares of argenx by 4.4% in the first quarter. Bank of New York Mellon Corp now owns 6,447 shares of the company's stock valued at $2,033,000 after purchasing an additional 271 shares during the period. Finally, US Bancorp DE raised its position in shares of argenx by 43.0% in the first quarter. US Bancorp DE now owns 1,798 shares of the company's stock valued at $566,000 after purchasing an additional 541 shares during the period. Institutional investors own 60.32% of the company's stock.

argenx Price Performance

NASDAQ ARGX traded down $4.48 during mid-day trading on Wednesday, reaching $366.20. 273,112 shares of the stock were exchanged, compared to its average volume of 320,319. argenx has a one year low of $327.73 and a one year high of $550.76. The stock has a 50 day simple moving average of $389.50 and a 200-day simple moving average of $422.65. The stock has a market cap of $21.72 billion, a P/E ratio of -71.25 and a beta of 0.65.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the prior year, the business earned ($0.70) EPS. Sell-side analysts anticipate that argenx will post -2.09 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.